Funding
XtalPi-Incubated Boundary Evolution Closes Over ¥100M Pre-A Round Led by Hua Capital, HSG and Xinglian
By News Desk ·
Key takeaways
- Boundary Evolution completed a Pre-A round exceeding 100 million yuan, its second financing within half a year.
- Hua Capital, HSG and Xinglian led the round, with Starlink Capital, Prosperity7, Harvest Capital, Huakong Fund and DT Capital Partners also investing.
- The company will use the funds for foundation model R&D, expansion of its high-throughput automated dry-wet closed-loop system and industrial ecosystem construction.
Boundary Evolution, a virtual cell company incubated by XtalPi, has completed a Pre-A round of more than 100 million yuan led by Hua Capital, HSG and Xinglian. 36kr reported the financing on November 16, 2026, describing it as the company's second round within half a year.
Hua Capital, HSG and Xinglian Back Boundary Evolution
The Pre-A round was jointly invested by Starlink Capital, Prosperity7, Harvest Capital, Huakong Fund and DT Capital Partners, with additional investment from existing shareholders Shunwei Capital, HSG and Songhe Capital. Boundary Evolution said the proceeds will support deep collaboration across cell response prediction, scientific hypothesis testing and high-throughput automated experimental feedback, and the construction of an AI biology platform spanning target discovery, virtual screening and clinical protocol optimization.
Co-founder Lai Lipeng said the round will be mainly used for foundation large model R&D, expansion of the high-throughput automated dry-wet closed-loop system and industrial ecosystem construction. "The scale of drug R&D lies not only in the precision of molecular engineering, but also in the depth of human understanding of complex life and disease mechanisms," Lai said, adding that the company hopes to couple massive biological data, large models and self-evolution methods to improve the certainty of innovative drug R&D.
Boundary Evolution's core asset is the OCOO series of virtual cell foundation models covering cellular multi-omics. The company has released OCOO-T, trained on transcriptome data, which models gene expression changes in cells under perturbation. In same-condition evaluations of the Tahoe100M, Replogle and PBMC single-cell perturbation benchmarks, OCOO-T achieved leading performance, according to the company.
Hua Capital's Fund Scale and Portfolio
Hua Capital's historical managed fund scale exceeds 200 billion RMB across multiple RMB and USD denominated funds, including Series I through IV RMB funds, a Series II USD fund, a parent fund and VC funds, according to akta.pro company records. The same records show cumulative invested integrated circuit projects exceeding 200 and more than 50 cultivated industry listed companies. Hua Capital was founded in 2018 and is headquartered in Beijing.
Orakl Oncology and Vale Biolabs Draw Virtual Cell Funding
Other virtual cell and organoid companies have also raised capital in November 2026. Paris-based Orakl Oncology raised $34 million in a Series A to scale its AI-driven virtual patient platform for cancer drug testing, Dealroom.co reported on November 12, 2026. Vale Biolabs received €164,000 from Venture Kick to advance its brain organoid platform, Startup Researcher reported on November 9, 2026.
Karl Workbench Benchmark Retest
In October 2026, in a retest of SciAgentArena, a scientific research agent benchmark jointly released by Yale University, the Broad Institute and other institutions, Boundary Evolution's Karl Workbench, equipped with the DeepSeek foundation model, ranked first in both the single-cell omics and spatial omics scenarios, according to information the company provided. Karl Workbench has entered internal testing.